Drug delivery embolization systems: a physician's perspective

Nicolini, Antonio; Crespi, S.; Martinetti, L

doi:10.1517/17425247.2011.590472

Cited by 18 publications

(17 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Transarterial chemoembolisation (TACE) has been used for over 30 years and is performed by local arterial infusion of the chemotherapeutic agent and subsequent injection of embolic particles [5]. Thus, it synergistically combines tumour starvation caused by embolisation [6,7], with the cytotoxic effect of drugs whilst minimising the systemic toxicity [8,9]. TACE has been demonstrated to be particularly effective for treating hypervascularised tumours and especially hepatic malignant lesions, which derive their main blood supply from arterial vessels [5].…”

Section: Accepted M Manuscriptmentioning

confidence: 99%

“…In order to address these issues, drug-eluting beads (DEBs) in the form of calibrated deformable microspheres have been introduced as embolic devices [14]. DEBs are generally biocompatible, non-degradable polymeric spheres loaded with specific molecules (i.e., anticancer drugs) which are released for prolonged time after injection and vessel occlusion [8,11,15,16]. This allows spatially controlled and simultaneous delivery of the anticancer drug and the embolic device in a single step, by means of microcatheters [7,17], providing improved controllability and reduced rate of trans-hepatic clearance compared to conventional TACE [5].…”

Section: Accepted M Manuscriptmentioning

confidence: 99%

See 1 more Smart Citation

Spatiotemporal dynamics of doxorubicin elution from embolic beads within a microfluidic network

Carugo

Capretto

Roy

et al. 2015

Journal of Controlled Release

View full text Add to dashboard Cite

Anticancer treatment using embolic drug-eluting beads (DEBs) has shown multifarious advantages compared to systemic chemotherapy. However, there is a growing need for a better understanding of the physical parameters governing drug-elution from embolic devices under physiologically relevant fluidic conditions. In the present study, we investigated the spatiotemporal dynamics of doxorubicin hydrochloride elution from drug-loaded hydrogel embolic beads within a microfluidic device, consisting of a network of interconnected microchannels, which replicates the architectural properties of microvascular systems. Drug-elution has been investigated experimentally at a single-bead level, using in-house developed microscopy-and spectrofluorimetry-based methods. Results demonstrated that the kinetics of drug-elution and the amount of eluted drug strongly depended on the location of the embolic event within the embolised channel (e.g. fractional amount of eluted drug after 3 hours was equal to ~0.2 and ~0.6 for completely-confined and partially-confined bead, respectively). Drug-elution from partiallyconfined bead showed a counterintuitive dependence on the local Reynolds number (and thus on the mean fluid velocity), as a result of dynamic changes in bead compressibility causing the displacement of the bead from the primary embolic site. Conversely, the kinetics of drug-elution from fully-confined bead was less affected by the local Reynolds number and bead displayed faster elution from the surface area exposed to the systemic flow, which was associated with the formation of fluid eddies nearby the bead post embolisation.

show abstract

Section: Accepted M Manuscriptmentioning

confidence: 99%

Section: Accepted M Manuscriptmentioning

confidence: 99%

Spatiotemporal dynamics of doxorubicin elution from embolic beads within a microfluidic network

Carugo

Capretto

Roy

et al. 2015

Journal of Controlled Release

View full text Add to dashboard Cite

show abstract

“…Drug-eluting Bead (DEB) technology has now been available to the physician for more than a decade and allows the delivery of the chemotherapy and the embolization agent concurrently [1, 2], simplifying the transarterial chemoembolization (TACE) procedure and allowing for a greater degree of standardization of the treatment (DEB-TACE) [3, 4]. Moreover, the controlled and sustained delivery of the drug offers an improved safety profile over conventional TACE due to lowered systemic levels of drug [5, 6].…”

Section: Introductionmentioning

confidence: 99%

Characterization of a novel intrinsically radiopaque Drug-eluting Bead for image-guided therapy: DC Bead LUMI™

Ashrafi

Tang

Britton

et al. 2017

Journal of Controlled Release

View full text Add to dashboard Cite

We have developed a straightforward and efficient method of introducing radiopacity into Polyvinyl alcohol (PVA)-2-Acrylamido-2-methylpropane sulfonic acid (AMPS) hydrogel beads (DC Bead™) that are currently used in the clinic to treat liver malignancies. Coupling of 2,3,5-triiodobenzaldehyde to the PVA backbone of pre-formed beads yields a uniformly distributed level of iodine attached throughout the bead structure (~150 mg/mL) which is sufficient to be imaged under standard fluoroscopy and computed tomography (CT) imaging modalities used in treatment procedures (DC Bead LUMI™. Despite the chemical modification increasing the density of the beads to ~1.3 g/cm3 and the compressive modulus by two orders of magnitude, they remain easily suspended, handled and administered through standard microcatheters. As the core chemistry of DC Bead LUMI™ is the same as DC Bead™, it interacts with drugs using ion-exchange between sulfonic acid groups on the polymer and the positively charged amine groups of the drugs. Both doxorubicin (Dox) and irinotecan (Iri) elution kinetics for all bead sizes evaluated were within the parameters already investigated within the clinic for DC Bead™. Drug loading did not affect the radiopacity and there was a direct relationship between bead attenuation and Dox concentration. The ability (Dox)-loaded DC Bead LUMI™ to be visualized in vivo was demonstrated by the administration of into hepatic arteries of a VX2 tumor-bearing rabbit under fluoroscopy, followed by subsequent CT imaging.

show abstract

“…Nano material carrier has certain adsorption and drug loading for some small molecule and peptide drugs with a quickly and sufficient targeted transport, but at the same time it can be adsorbed easily by normal tissue which resulted in certain poisonous effect [19]. Liposomes and polymer materials as targeted carriers may have targeted and specific defects [20]. Monoclonal antibody carrier accompany with a high cost and complicated process.…”

Section: Discussionmentioning

confidence: 99%

Targeting PEPT1: a novel strategy to improve the antitumor efficacy of doxorubicin in human hepatocellular carcinoma therapy

Gong

Wang

et al. 2017

Oncotarget

View full text Add to dashboard Cite

Proton coupled oligopeptide transporter 1 (PEPT1) is a member of the peptide transporter superfamily and plays important role in the absorption of oligopeptide and peptidomimetic drugs. Our previous research verified that PEPT1 expressed specifically in human Hepatocellular carcinoma (HCC) tissue and cell lines and showed potential transport activity to be a new candidate of the tumor therapeutic target. In this study, we aim to explore the feasibility of a novel tumor target therapeutic strategy: Targeting PEPT1 to improve the antitumor efficacy of Doxorubicin in human HCC therapy. First, Doxorubicin was conjugated with Glycylglycylglycine (Gly-Gly-Gly) − a tripeptide which was known as the substrate of PEPT1 and characterized by HPLC and MS successfully. Doxorubicin-tripeptide conjugate was then observed to clarify the target delivery by PEPT1 and the antitumor effect on human hepatocarcinoma in vivo and in vitro. Furthermore, the improvement of the toxic and side effect of Doxorubicin after conjugation was also evaluated by some biochemical tests. Our results reveal that targeting PEPT1 may contribute to the efficient delivery of Doxorubicin to hepatocarcinoma cells and the reduction of drug toxicity. PEPT1 has the prospect to be a novel target of HCC therapy.

show abstract

Drug delivery embolization systems: a physician's perspective

Abstract: The management of the treatment of focal liver lesions is a difficult process, which must involve various specialists such as the interventional radiologist. The use of drug-eluting microspheres seems to improve the results of TACE both in HCC and in colorectal liver metastases.

Cited by 18 publications

References 56 publications

Spatiotemporal dynamics of doxorubicin elution from embolic beads within a microfluidic network

Spatiotemporal dynamics of doxorubicin elution from embolic beads within a microfluidic network

Characterization of a novel intrinsically radiopaque Drug-eluting Bead for image-guided therapy: DC Bead LUMI™

Targeting PEPT1: a novel strategy to improve the antitumor efficacy of doxorubicin in human hepatocellular carcinoma therapy

Contact Info

Product

Resources

About